Skip to main content
Signal8

REGENERON PHARMACEUTICALS, INC. (REGN) Form 8-K — Oct 30, 2026

$REGNForm 8-KItems 2.02, 9.01Filed Oct 30, 2026, 6:50 AM ET0000872589-26-000032Original filing

Regeneron reported Q3 2026 revenues of $5.1 billion, up 36% year over year, with GAAP EPS of $18.45 (+35%) and non-GAAP EPS of $20.07 (+70%). Growth was driven by record net sales for Dupixent ($6.5B global, +35%), EYLEA HD ($699M US, +62%), and Libtayo ($550M global, +51%), plus a 68% jump in Sanofi collaboration revenue after full repayment of the Development Balance. Legacy EYLEA US sales fell 41% on competitive pressure. Regeneron also expanded its Sanofi antibody collaboration with a $1.0 billion upfront (to be booked in Q4 2026) and up to $7.0 billion in additional milestones, and the FDA approved Pasatru (garetosmab) for fibrodysplasia ossificans progressiva.

Key figures

Eps
18.45
Revenue
5116
Guidance
Updated FY2026 guidance: GAAP R&D $6.600-$6.735B (raised), non-GAAP R&D $6.050-$6.150B, GAAP SG&A $2.730-$2.860B (lowered), non-GAAP gross margin ~86%, GAAP ETR ~14%, capex $1.050-$1.100B
Net Income
1949
Total Debt
1,987.0 million long-term debt
Revenue Yoy
36%
Total Assets
44,405.2 million
Cash Position
18,858.5 million (cash and marketable securities)
Shares Outstanding
101.7 million basic weighted average
Non gaap eps yoy
70%
Dividend per share
$0.94
Eylea us net sales
$400 million (-41%)
Gaap net income yoy
33%
Non gaap eps q3 2026
20.07
Eylea hd us net sales
$699 million (+62%)
Libtayo global net sales
$550 million (+51%)
Sanofi expansion upfront
$1.0 billion
Buybacks nine months 2026
$2.3 billion
Dupixent global net sales
$6.5 billion (+35%)
Buyback capacity remaining
$2.2 billion
Free cash flow nine months
$2,904.3 million
Sanofi collaboration revenue
$2,724 million (+68%)
Sanofi expansion potential milestones
up to $7.0 billion

AI analysis

Red flags4 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.